Overview

Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies how well ursodiol works in treating patients with Barrett esophagus or cells that look abnormal under a microscope but are not cancer (low-grade dysplasia). Chemoprevention is the use of certain drugs to keep cancer from forming. The use of ursodiol may keep cancer for forming in patients with Barrett esophagus or low-grade dysplasia.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Ursodeoxycholic Acid